ADMA Biologics has developed a method for treating upper respiratory infections caused by Streptococcus pneumonia. The method involves administering a hyperimmune globulin composition containing antibodies specific to multiple S. pneumonia serotypes. This innovative approach aims to prevent and treat pneumococcal infections, especially in immunocompromised individuals. GlobalData’s report on ADMA Biologics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights ADMA Biologics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ADMA Biologics, Anti-viral antigen-based compositions was a key innovation area identified from patents. ADMA Biologics's grant share as of February 2024 was 62%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of upper respiratory tract infection with immunotherapeutic composition

Source: United States Patent and Trademark Office (USPTO). Credit: ADMA Biologics Inc

A recently granted patent (Publication Number: US11897943B2) discloses a method for treating upper respiratory tract infections using an immunotherapeutic composition. The method involves administering a therapeutically effective amount of immune globulin prepared from pooled plasma samples of healthy adult human plasma donors vaccinated with anti-pneumococcal vaccines. The pooled plasma contains opsonophagocytic antibody titers specific for at least 7 or more S. pneumonia serotypes, with significantly higher antibody titers compared to a control sample. The method can be used for both therapeutic and prophylactic treatment of upper respiratory tract infections, and may also involve administering other biologically active agents such as antibodies, anti-inflammatory agents, antimicrobial agents, and more.

Furthermore, the immunotherapeutic composition may include mono-specific, bi-specific, or multi-specific antibodies targeting bacterial or fungal toxins like Botulinum neurotoxin, Tetanus toxin, and Staphylococcal toxins. The composition also comprises neutralizing antibodies specific for various pathogens such as Corynebacterium diphtheria, measles virus, and polio virus. The method is suitable for a wide range of patients, including those with primary immunodeficiency diseases, end-stage renal disease, autoimmune diseases, and patients in acute care settings. The composition aims to treat or prevent upper respiratory tract infections caused by S. pneumonia by boosting the immune response with high levels of specific antibodies. Overall, the patent highlights a novel approach to combating respiratory infections using a specialized immunotherapeutic composition.

To know more about GlobalData’s detailed insights on ADMA Biologics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies